Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Solarboom 2024: Fünf Gründe, die für diese Aktie sprechen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DR0J | ISIN: US3621LQ1099 | Ticker-Symbol: G1H
Tradegate
23.04.24
10:00 Uhr
4,028 Euro
+0,118
+3,02 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
G1 THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
G1 THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,8684,02613:56
3,8684,02613:32

Aktuelle News zur G1 THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.04.G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 20241
12.04.Breaking Down G1 Therapeutics: 5 Analysts Share Their Views2
04.04.G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference4
01.04.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)41RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable...
► Artikel lesen
22.03.G1 Therapeutics, Inc. - 8-K, Current Report3
20.03.G1 Therapeutics CFO sells over $19k in company stock5
01.03.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)242RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable...
► Artikel lesen
01.03.Earnings call: G1 Therapeutics reports strong Q4 growth, eyes TNBC leadership5
29.02.G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript2
28.02.G1 Therapeutics rises on Q4 revenue beat4
28.02.G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights191- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million -...
► Artikel lesen
28.02.G1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1.87M6
28.02.G1 Therapeutics, Inc. - 8-K, Current Report2
27.02.G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference3
15.02.G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 20245
13.02.Why Is Breast Cancer-Focused G1 Therapeutics Stock Trading Lower Today?8
13.02.G1 Therapeutics, CareCloud among healthcare movers6
13.02.Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?13
13.02.Pre-market Movers: Ohmyhome, ARB IOT, Farmmi, Biodexa Pharmaceuticals, G1 Therapeutics709BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.50 A.M. ET).In the Green Ohmyhome Limited (OMH) is up over 351% at $5.51. ARB...
► Artikel lesen
13.02.G1 Therapeutics down after lead cancer therapy fails to meet study goal12
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1